LINC vs UTI

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where LINC advanced for three days, in 259 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

LINC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LINC as a result. In 77 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LINC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.

The Aroon Indicator for LINC entered a downward trend on October 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LINC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.

The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LINC's P/B Ratio (3.442) is slightly higher than the industry average of (1.349). P/E Ratio (29.676) is within average values for comparable stocks, (9.780). Projected Growth (PEG Ratio) (1.557) is also within normal values, averaging (1.327). Dividend Yield (0.004) settles around the average of (4.828) among similar stocks. P/S Ratio (1.383) is also within normal values, averaging (27.566).

The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. LINC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where UTI's RSI Indicator exited the oversold zone, 13 of 17 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on UTI as a result. In 83 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.

Following a +5.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where UTI advanced for three days, in 258 of 329 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

UTI broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for UTI entered a downward trend on October 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. UTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.

The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: UTI's P/B Ratio (3.328) is slightly higher than the industry average of (1.349). UTI has a moderately high P/E Ratio (33.548) as compared to the industry average of (9.780). Projected Growth (PEG Ratio) (1.642) is also within normal values, averaging (1.327). Dividend Yield (0.004) settles around the average of (4.828) among similar stocks. P/S Ratio (1.320) is also within normal values, averaging (27.566).

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.